Humanigen (OTCMKTS:HGEN) CEO Cameron Durrant joined Steve Darling from Proactive Investors in Los Angeles at the LD Micro show to provide details about their latest research regarding the use of Car-T therapy in the treatment of certain blood cancers. That research was just published in the digital version if Blood Magazine.
viewHumanigen, Inc.
Humanigen new research shows encouraging results for cancer treatment using Car-T
Quick facts: Humanigen, Inc.
Price: - -
OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Health
CytoDyn provide update on their path to approval for treatment of COVID-19
6 days, 4 hours ago
Mining
Wheaton Precious Metals will be the largest gold and silver-focussed company...
10 hours, 14 minutes ago
Energy
NA Proactive news snapshot: ElectraMeccanica Vehicles, Willow Biosciences,...
2 hours, 33 minutes ago
